Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 9/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 9/20 | 1.00 |
| ▸ | MET | P08581 | 7/20 | 1.00 |
| ▸ | SRC | P12931 | 6/20 | 1.00 |
| ▸ | LCK | P06239 | 4/20 | 1.00 |
| ▸ | YES1 | P07947 | 4/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | CASK | O14936 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pha-665752 SCHEMBL29376386 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93656 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93657 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93655 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL140412 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL15639801 | 0.99 | KDR (0.99) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL15639803 | 0.99 | KDR (0.99) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL23691031 | 0.97 | KDR (0.94) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL143795 | 0.96 | KDR (0.93) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL147331 | 0.95 | KDR (0.91) | KDRFGFR1PDGFRBMETSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729043-B2 | Anti-Met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products | METHERESIS TRANSLATIONAL RESEARCH S.A. (CH) | 2014-05-20 | — | — | US | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| EP-1981981-B1 | ANTI-MET MONOCLONAL ANTIBODY, FRAGMENTS AND VECTORS THEREOF, FOR THE TREATMENT OF TUMORS AND CORRESPONDING PRODUCTS | METHERESIS TRANSLATIONAL RES SA (CH) | 2011-06-29 | — | — | EP | claimed |
| US-20090285807-A1 | Anti-Met Monoclonal Antibody, Fragments and Vectors Thereof, for the Treatment of Tumors and Corresponding Products | Pierre Fabre Médicament (FR) | 2009-11-19 | — | — | US | claimed |
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | claimed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | claimed |
| WO-2002096361-A2 | 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2002-12-05 | — | — | WO | claimed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-4545100-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4541380-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| WO-2007009613-A1 | METHOD FOR MEASURING TYROSINE KINASE PHOSPHORYLATION | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20060246492-A1 | Method for predicting responsiveness to drugs | THE GENERAL HOSPITAL CORPORATION (US) | 2006-11-02 | — | — | US | disclosed |
| US-20060035907-A1 | Methods of treating abnormal cell growth using c-MET and m-TOR inhibitors | CHRISTENSEN JAMES G | 2006-02-16 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005082411-A1 | METHOD OF TREATING ABNORMAL CELL GROWTH USING C-MET AND-TOR INHIBITORS | SUGEN, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035907-A1 | Methods of treating abnormal cell growth using c-MET and m-TOR inhibitors | MET, MTOR, MYC | KDR 252/4885FGFR1 68/4885PDGFRB 560/4885 |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, RXFP3, NPY2R | KDR 2878/4885FGFR1 2771/4885PDGFRB 4228/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | KDR 3515/4885FGFR1 2064/4885PDGFRB 4669/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | KDR 1077/4885FGFR1 5/4885PDGFRB 467/4885 |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | KDR 398/4885FGFR1 637/4885PDGFRB 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.